$70.780
-5.309 (-7.50%)收盤時
TMDX 資訊
TMDX 事件
TransMedics Appoints Fernando Araujo as CFO
TransMedics appointed Fernando Araujo as CFO, effective September 21. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Advisor, LATAM to lead TransMedics' expansion into Latin America. Araujo most recently served as CFO of GE HealthCare's Advanced Imaging Solutions segment. He previously served as GE HealthCare's Corporate Finance CFO . In addition, Araujo served as the SVP of Finance for Enterprise Operations at 3M. Earlier in his career, during a 17-year tenure at General Electric, he held a series of senior finance and CFO roles.
TransMedics Backs 2026 Revenue View of $737M-$757M
TransMedics backs 2026 revenue view $737M-$757M, consensus $741.71M
FY26 Revenue Guidance Expected at $733.18M
FY26 consensus $733.18M. This guidance excludes any revenue attributable to the recent strategic investment in PAD Aviation service GmbH, assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials, and represents approximately 22% to 25% growth compared to the company's prior year revenue.
TransMedics Reports Q2 Revenue of $189.9M
Reports Q2 revenue $189.9M, consensus $183.99M. "The second quarter was a defining one for TransMedics: record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities," said Waleed Hassanein, MD, President and Chief Executive Officer. "Let me be direct about how we see our business: we are building TransMedics to remain a growth company in the near, mid, and long terms. We are deploying capital behind four distinct growth opportunities that we believe will drive substantial revenue growth with a compelling operating profile at scale. Our confidence is derived from our team's proven track record of converting investment into results, quarter after quarter. It is also grounded in the unparalleled nature of our offering: the life-saving impact of our OCS technology, the reach of our NOP platform, and the extraordinary people who deliver it. Our mission has not changed - expand access and improve outcomes for every patient waiting for an organ transplant. We are more inspired by what lies ahead than at any point in our history."
TransMedics Stock Rises 8.0% to $76.90
TransMedics is up 8.0%, or $5.67 to $76.90.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。